\
&
Contact us
\
&
Contact us
Published on | 7 months ago
Programmes ERCThe FRONTIERS team invites research institutions and projects to express their interest in hosting a science journalist as part of the FRONTIERS Residency Programme, by joining the database of potential host institutions. The FRONTIERS public database is a starting point for applicants when identifying a host institution, though inclusion in the database is not required to be eligible as a host.
Expression of interest form (for institutions)
What is FRONTIERS?
FRONTIERS is the science journalism initiative funded by the European Research Council (ERC) to design a residency programme for science journalists wishing to experience an immersive period in a European research institution.
The FRONTIERS project is set to run from 2023 to 2027. During this time, the FRONTIERS team plans four calls to enable up to 40 science journalists to spend time with research teams, working on their own reporting ideas at institutions of their choice. Fellows and residency projects from previous rounds can be consulted here.
While backing independent science journalism, FRONTIERS hopes to contribute to the public trust in scientific institutions and in the scientific method itself, to ensure European citizens have access to reliable and accurate scientific reporting, to tackle misinformation and disinformation, ultimately contributing to more informed policymaking and a more scientifically literate society.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Horizon Europe Digital Europe
Building on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
